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1. Introduction 
Mental retardation is a common disorder, affecting 2.5% 
of the population and ranging in severity from mild to 
profound. Although most often found in association with 
congenital or chromosomal abnormalities (e.g., Down's 
syndrome) or consequential to disorders of metabolism 
(e.g., phenylketonuria), a large number of cases are of 
unknown cause. It has long been recognised that males 
consistently outnumber females in surveys of mentally 
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retarded individuals and linkage stadies have identified 
many loci associated with mental retardation on the X 
chromosome. The most common of these X-linked disor- 
ders, accounting for 50% of cases, is the fragile X syn- 
drome. 
The identification of the molecular basis of this disorder 
has clarified some of the previously puzzling genetic and 
clinical features and has also revealed a new class of 
mutations responsible for inherited iseases in man. 
2. Clinical and cytogenetic features 
The fragile X, or Martin-Bell, syndrome was reported in 
1943 [ 1 ] in the first pedigree with mental retardation linked 
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to the X-chromosome. It has since been found to be the 
most common form of inherited mental retardation, with 
an estimated frequency of between 0.3 and 1 per 1000 live 
births in males and 0.2-0.6 per 1000 in females [2-4] with 
a worldwide distribution. The disease is inherited as an 
X-linked semidominant condition where 50-55% of car- 
rier females manifest the disease and 20% of males are 
phenotypically normal carriers. 
The fragile X syndrome was originally distinguished 
from the many other forms of X-linked mental retardation 
by the identification of a microscopic gap or constriction, 
termed a fragile site, in the long arm of the X chromosome 
at Xq27.3 in affected individuals [5-7]. The cytogenetic 
expression of the fragile site can be induced by culturing 
cells in conditions of folate deficiency, excess thymidine 
or in the presence of chemicals which disrupt folate 
metabolism (see Fig. 1). Many fragile sites have been 
described in human chromosomes but only two of these, 
the site associated with fragile X syndrome and a site 
located 0.6 Mb distal to it, have so far been associated 
with disease. Prior to the ascertainment of the molecular 
basis of the disease, routine diagnosis entailed time-con- 
suming and costly cytogenetic analysis of patients and 
family members. 
Fragile X males have mental retardation varying be- 
tween moderate and profound. This is often accompanied 
by a typical facial dysmorphology consisting of a long face 
with prominent forehead, pronounced jaw and large ears. 
Macroorchidism can develop at puberty, suggesting the 
involvement of an endocrine dysfunction. This is the clas- 
sical fragile X syndrome [8]. However, the clinical expres- 
sion can often be extremely variable. Some patients how 
behavioural abnormalities such as hyperactivity, poor so- 
cial contact or autism [9] and there may also be connective 
tissue involvement presenting as joint laxity or heart ven- 
tricular defects. Female carriers are usually less severely 
affected than males [10]. 
The syndrome shows unusual genetic characteristics in 
that the pattern of inheritance does not follow the classical 
Mendelian pattern for X-linked genes. Normal males can 
transmit he fragile X mutation to their daughters. These 
males, who are themselves clinically and cytogenetically 
normal, have been termed 'normal transmitting males' 
(NTMs). In addition, there is incomplete penetrance of the 
phenotype in different generations of families which segre- 
gate for the disorder. The sisters of NTMs are almost never 
affected and neither are their daughters. However, the 
sisters of affected males show a 35% penetrance for the 
C 
i ii 
× 
Fig. 1. Two G banded fragile X chromosomes from different metaphases viewed by Scanning Electron Microscopy (SEM). The upper inserts how 
non-banded chromosomes from the same individual viewed by light microscopy (LM) and demonstrating theconsistency ofthe gross morphology. (A) The 
fragile site appears as an isochromatid gap in both the LM and SEM pictures. (B) The fragile site appears as a chromatid gap on the right hand chromatid, 
with the fragment almost completely detached. (C) A diagrammatic representation of the X chromosome showing the G positive bands (i) subdivided into a 
series of sub-bands (ii) indicated as arrows, also shown on the SEM pictures. The numbering system used as indicated at the left hand side (i) places the 
fragile site at the distal end of Xq27. Photograph reproduced from [108] courtesy of the publishers. 
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Fig. 2. Typical pedigree of a family showing inheritance of the fragile X 
syndrome. As the abnormal X chromosome is passed from generation to 
generation, the risk of mental impairment (shown as a percentage) tothe 
offspring inheriting this X chromosome increases. 
disease. The daughters of NTMs have a high probability 
(40%) that offspring who inherit the abnormal X chromo- 
some will be clinically affected and the risk increases in 
the next generation to 50%. A typical fragile X pedigree is 
shown in Fig. 2. In this family, the carrier female in the 
first generation passes the mutation to her son, who is 
unaffected. The daughter of this NTM must inherit his X 
chromosome and she has two children, an affected boy and 
a carrier daughter. Her daughter has an even higher risk of 
having affected children. Thus the likelihood of developing 
mental retardation is dependent upon the position of the 
individual in the pedigree. This observation, which was 
originally known as the 'Sherman paradox' [11,12] is an 
example of the phenomenon called genetic anticipation. It
has since been explained by the discovery that the gene 
associated with the disease contains a polymorphic trinu- 
cleotide CGG repeat which expands and becomes highly 
methylated in affected individuals, causing the gene to be 
silenced. 
3. Isolation of the gene associated with fragile X syn- 
drome 
In common with many genetic diseases where no obvi- 
ous protein candidate is available, the gene responsible for 
fragile X syndrome was localised by positional cloning 
[13]. In the case of fragile X syndrome, this process was 
facilitated because the fragile site localised the disease at 
Xq27.3. 
Three approaches led to the cloning of the gene. The 
first involved the use of hybrid cell lines containing small 
portions of the X chromosome which included the fragile 
site region from which random DNA markers were iso- 
lated [14-16]. The second involved the production of a 
library containing the microdissected region of the fragile 
site [17]. The third approach was the construction of 
somatic cell hybrids containing the X chromosome from a 
fragile X patient on a hamster background, the hypothesis 
being that the human chromosomes were likely to break at 
the fragile site. The hybrid cells were cultured to induce 
fragile X expression and selection for genes on either side 
of the fragile site led to the isolation of several new 
somatic cell hybrids which contained translocations be- 
tween the human and hamster material. Such events were 
postulated to preferentially occur in the region of the 
chromosomal fragility [18]. The markers generated from 
these studies were used to analyse genomic DNA sepa- 
rated by pulse field gel electrophoresis (PFGE) and a 
physical map of the region was constructed. The use of 
rare cutting enzymes, sensitive to methylation, led to the 
discovery that a cluster of CpG residues were specifically 
hypermethylated in fragile X patients [19,20]. Such clus- 
ters of methylation-sensitive sites, usually termed CpG 
islands, are normally unmethytated and are known to be 
associated with genes [21]. 
Yeast artificial chromosomes (YACs) spanning the 
methylated CpG island were shown by fluorescence in situ 
hybridisation to span the fragile site: [22-24]. Sequencing 
of cosmids derived from the YACs. revealed a sequence 
lying less than 300 bp distal to the CpG island. This 
sequence consists of a repeated motif of three nucleotides 
(CGG) which becomes abnormally amplified in individu- 
als affected with fragile X syndrorae. The expansion of 
this trinucleotide repeat was also suggested as the cause of 
the instability of the fragile X chromosomes [25,26]. At the 
same time, the cosmids were used to isolate an expressed 
sequence from fetal brain which was called FMRI (fragile 
X mental retardation-l) [27]. The trinucleotide repeat was 
found to be present in the 5' untrznslated region of the 
cDNA sequence. 
4. The nature of the trinucleotide ~repeat 
The number of CGG repeats in tlhe normal X chromo- 
some varies between 6 and 53 copies with 29 copies 
occurring most frequently. Within this normal range, the 
alleles are stably inherited [24,28]. Allele sizes of between 
54 and 200 copies are termed premutation sized alleles, 
since they generally belong to individuals who carry the 
disease gene but show no phenotypic effects. Full mutation 
alleles always contain more than 200 repeats. Fig. 3 shows 
a diagrammatic representation of the expansion of the 
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Fig. 3. Schematic representation f the FMR1 gene, showing the relative 
positions of the CpG island and the trinucleotide CGG repeat, which is 
unstable and expands to give rise to the fragile X phenotype. 
repeat within the FMR1 gene. The premutation alleles are 
unstable and this instability increases with the size of 
repeat. Normal transmitting males and their daughters 
often show premutations with small expansions. The risk 
of expansion to the full mutation is dependent on the size 
of the premutation allele. If the repeat number is small 
(50-70 copies) then the risk is low; if the repeat number is 
high (> 90 copies) the risk is almost 100%. The risk of 
expansion is also dependent upon the purity of the repeat. 
Sequencing has shown that in normal individuals the CGG 
repeat can be interrupted by single base differences leading 
to imperfect repeats [29] and it appears that these do not 
show the same degree of instability as the pure repeats. 
The premutation alleles change in size at female (and 
more rarely in male) meiotic transmission. In most in- 
stances the allele increases in size, although in rare cases 
reduction has also been observed [25,26]. Since affected 
males rarely reproduce, a very high mutation rate (1/3,000) 
has been suggested to maintain the frequency of the dis- 
ease [30]. However, direct testing has not revealed any 
new mutations. A model has been proposed to account for 
the molecular observations [31] which postulates four alle- 
les ranging in size from one containing a normal stable 
insert, two progressively arger and more unstable inserts 
and finally one with a large insert which gives rise to the 
fragile X phenotype. Evidence in support of this model has 
been obtained using microsatellite r peats closely linked to 
FMRI. These show linkage disequilibrium with the disor- 
der indicating that a small number of founder chromo- 
somes are responsible for approximately 55% of the ob- 
served fragile X-linked haplotypes in the Caucasian popu- 
lation [32-37]. Many of the chromosomes a sociated with 
these haplotypes have a CGG repeat length of approxi- 
mately n = 29 or higher, which is close to the unstable 
length. These alleles may already have a slightly increased 
instability [25,27]. Over generations such alleles could gain 
more repeats which would increase their instability. The 
recurrence of low frequency events arising on a specific 
chromosome background and taking many generations to 
develop into a full mutation may account for both the high 
frequency of the disease and the finding of linkage disequi- 
librium. 
Transmission through females is essential to generate an 
expansion size which will manifest the disorder. However 
changes in size of the CGG array can occur during both 
meiosis and mitosis, the latter giving rise to somatic 
mosaicism in fragile X individuals [25,26,28]. The pres- 
ence of these two forms of instability together with X-in- 
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Fig. 4. Model for polymerase slippage as a method for the generation of expansions in tandem repeats. (Figure adapted from [38].) (Left) Initial copy 
number < 80 has a probability that only 1 single stranded break will occur during replication, consistent with the approximate l ngth of an Okazaki 
fragment ( * ). Slippage of the elongated strand during polymerisation can result in the addition or deletion of a few copies of the repeat. (Right) Initial copy 
number > 80 has a probability that 2 or more single stranded breaks will occur during replication. The strand between these breaks is not anchored and is 
therefore free to slide during polymerisation, enabling the addition of many more copies than were present in the original sequence. 
A. V. Flannery et al. / Biochimica et Biophysica Acta 1271 (1995) 293-303 297 
activation in females may explain why the phenotypic 
expression of the disease is variable. 
The exact mechanism involved in the generation of 
expansions i not clear. The involvement of factors acting 
in either cis or trans have been postulated but there is little 
evidence thus far. One possible mechanism for expansion 
is based on the misalignment of replicating DNA with 
subsequent polymerase slippage. Fig. 4 shows a represen- 
tation of the model proposed by Richards and Sutherland 
[38]. The mechanism requires the presence of two single 
strand breaks occurring within the repeat during replica- 
tion. The longer the repeat, the more likely two such 
breaks will occur together within the sequence. In this 
configuration the strand of DNA between the breaks (an 
Okasaki fragment) is able to slip or slide during polymeri- 
sation. Such events have been observed in vitro [39]. The 
repair of the products of these events would be expected to 
lead to the introduction of many more copies of the repeat 
than were present in the original sequence. This could 
account for the generation of persistently longer alleles 
over many cell cycles. 
An alternative mechanism, implicated in the generation 
of germline mutations in human minisatellites [40,41] has 
also been proposed to account for trinucleotide expansions. 
Complex gene conversion events are thought o play a role 
in this type mutation and such events are known to be 
involved in trinucleotide repeat reversions [42]. The min- 
isatellite mutation results in a gain in copy number being 
polarised at one end of the repeat. 
Analysis of the internal structure of the FMR1 
trinucleotide r peat has shown that it is in fact a composite 
array with sets of CGG trinucleotides interrupted by regu- 
larly spaced AGG trinucleotides giving a defined structure 
to the array [29,43]. The variable length in the population 
is due to variable numbers of such interrupted blocks 
averaging nine CGG triplets. Thus a typical array would be 
(CGG)9(AGG)(CGG)9(AGG)(CGG) 9. Around 3-5% of the 
population, however, carry uninterrupted arrays with 
greater than 20 CGG triplets either alone or at the 3' end of 
the array. These arrays occur more frequently on chromo- 
somes with a high risk flanking haplotype, suggesting that 
they may be precursor arrays from which fragile X chro- 
mosomes have arisen by further slippage events. Further- 
more, a comparison of the length of these arrays suggests 
that they have arisen by the loss of the interspersed AGG 
triplet, thus the reported linkage disequilibrium ight be 
due to such a founder event. 
The unstable nature of the amplification event is further 
complicated since it is not clear when the expansion 
occurs. It is known that the transition from premutation to
full mutation occurs exclusively in the maternally-trans- 
mitted allele. However, it is possible that the transition 
occurs in the somatic cells of the developing embryo, 
rather than in the germline cells of the mother. Evidence 
suggests that fragile X affected fetuses are mosaic with 
respect o the trinucleotide xpansion and that following 
the establishment of mosaicism the repeat becomes tably 
transmitted in somatic tissue [44,45]. These observations 
could result from multiple independent transitions in many 
different embryonic ell lineages [4.5]. Such a hypothesis 
depends upon the transition from premutation to full muta- 
tion occurring in the early zygote and could result from an 
imprint on the maternally derived X chromosome. Mosaic 
individuals with both pre and full mutation alleles would 
result from transition in some but not all lineages. This 
also implies that the transition is not present in the germline, 
since the mothers must contribute a premutation allele. The 
sperm cells of affected males show only premutation sized 
alleles, suggesting either that the transition does not occur 
in the germline, and is only present in mitotic cells [46] or 
that there is selection against the full mutation due to a 
requirement of FMR1 expression in these cells or their 
precursors. Direct analysis of oocytes isolated from premu- 
tation carriers is required to resolve this question. 
The CGG repeat is localised i~a the 5' untranslated 
region of FMR1 close to a CpG ishmd which is normally 
unmethylated on the active X chromosome and methylated 
on the inactive X chromosome [25,47]. Mutant FMR1 
alleles are always hypermethylated over a region which 
includes the 5' CpG island and the CGG repeat 
[19,23,25,47,48]. In lymphobtasts, leucocytes and fibrob- 
last of fragile X males, the FMR! gene appears to be 
transcriptionally inactive [49], the loess of expression corre- 
lating with the methylation status of the CpG island. 
Recent work has defined the FMR] promoter which lies 
within this region and has shown that it is completely 
inhibited by methylation i  vitro [50]. Methylation of the 
region down-regulates FMR1 expression resulting in the 
disease. 
It is uncertain whether abnormal methylation occurs in 
response to the expansion of the CGG repeat or whether 
methylation is responsible for the expansion. Normal trans- 
mitting males do not show methylation. Prenatal diagnosis 
using DNA from chorionic villi taken at the 10th week of 
gestation has shown the full mutation in fetal DNA both 
with and without methylation [35,51,52]. This is earlier 
than the methylation caused by lionisation, which is not 
yet complete by 10 weeks gestation [53]. Taken together, 
the data suggest hat methylation occurs after the expan- 
sion. 
Several lines of evidence strongly suggest that the 
expanded CGG repeat gives rise to the chromosomal dis- 
ruption presenting as a fragile site. First, the fragile site is 
only seen in patients with expansior~s of greater than 200 
repeats. A positive correlation between the mean insert 
size and the level of cytogenetic expression has been 
demonstrated [54,55]. In addition, fluorescence in situ 
hybridisation places the repeat in physical proximity with 
the fragile site [56]. Furthermore, cytogenetic expression of 
the fragile site does not occur in individuals whose fragile 
X phenotype is due to deletions or point mutations in the 
FMR1 gene [57-60]. Finally, the identification of another 
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fragile site on the X chromosome (FRAXE)  localised 600 
kb distal to FMR1 with the same underlying molecular 
basis (the expansion of a CGG repeat) [61] also argues in 
favour of the CGG repeat being responsible for the chro- 
mosomal disruption; none of the diseases caused by expan- 
sion of CAG repeats are associated with fragile sites. 
Delayed replication of the FMR1 gene in affected individ- 
uals has been observed, possibly due to the unusual config- 
uration of DNA containing high GC content [62]. This 
phenomenon may be associated with the chromosomal 
fragility. 
5. The FMR1 gene 
Since the original discovery of the FMR1 cDNA [27], 
evidence has mounted that FMR1 is the primary gene 
involved in the fragile X phenotype. This includes the 
silencing of FMR1 transcription in most fragile X patients 
due to methylation [46], the apparent absence of other 
genes lying close to FMR1 [23] and the very significant 
finding of fragile X patients with deletions or a point 
mutation in the FMR1 gene [57-60,63]. 
The FMR1 gene is evolutionarily conserved, at least to 
the level of vertebrates [27]. The 4.36 kb mRNA encodes a
protein of a predicted size approximately 70 kDa (631 
amino acids). Alternative splicing events give rise to up to 
12 distinct mRNA products, most of which differ at the 3' 
end [64,65]. This may allow functional diversity, although 
none of the alternative isoforms has been found so far to 
have tissue specificity. The structure of the human gene 
has been determined [66] and consists of 17 exons span- 
ning 38 kb of DNA. The intron-exon boundaries have been 
analysed and splice donors and acceptors at the 3' end of 
the gene show less adherence to consensus, correlating 
with the observed alternative splicing. 
6. A possible role for FMR1 
No significant similarity has been found between FMR1 
or its inferred amino acid sequence and any known cDNAs 
or proteins in the Genbank and SwissProt databases. How- 
ever, analysis of predicted amino acid motifs has revealed 
sequences in FMR1 characteristic of RNA-binding pro- 
teins [67,68]. 
Amino acids 286-321 and 347-382, lying close to- 
gether in the central portion of the protein, are internal 
repeats which have strong similarity to the KH domain 
which has been found to occur in hnRNP K proteins found 
in the hnRNP complexes involved in the biogenesis of 
mRNA [69]. The K protein binds strongly to sequences 
rich in cytidine and is the major oligo (rC/dC)-binding 
protein in vertebrate cells. The KH domain has also been 
identified in several other proteins, some of which are 
known to be RNA-binding proteins. These include the 
archaebacterial ribosomal protein $3 [70] and the yeast 
meiosis-specific splicing regulator MER-1 [71,72] (see Fig. 
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Fig. 5. Primary amino acid structure of the FMR1 protein and comparison to known RNA binding proteins. Letters refer to the single letter amino acid 
code. (A) KH domains in two regions of FMR1 protein showing similarity at the amino acid level to several known or putative RNA binding proteins. 
Highly conserved residues are boxed. (B) RGG box in FMR1 protein and similar domains in other RNA binding proteins. (C) Schematic representation of 
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5A). An important piece of evidence that the KH domain 
is critical for the function of the FMR1 gene product is the 
finding of an individual with a very severe fragile X 
phenotype who does not carry the typical trinucleotide 
amplification, but instead has a single point mutation in 
one of the most highly conserved residues of the KH 
domain resulting in the conversion of I1e-367 to Asn [63]. 
A second domain, near the carboxyl end of the protein 
contains an arginine- and glycine-rich domain consisting 
of clusters of the tripeptide repeat ermed the RGG box 
[73]. This motif has been demonstrated to have RNA 
binding activity and is present at the C-terminus of a 
number of nuclear RNA-binding proteins from diverse 
organisms. These include the hnRNP A1 protein, which is 
an abundant nucleoplasmic phosphoprotein [74], and fibril- 
latin [75] (see Fig. 5B). 
Since both the KH domain and the RGG boxes are 
strong predictors of RNA binding activity, it has been 
speculated that the FMR1 protein (FMRP) may interact 
with other genes. The products of such genes could there- 
fore vary in the absence of FMRP, contributing to the 
pleiotropic phenotype seen in the fragile X syndrome. 
FMRP has been transcribed and translated in vitro and the 
translation product shows strongest binding to the RNA 
homopolymer poly(G) [67]. Mutagenesis of conserved 
residues within either KH domain, or deletion of the RGG 
box all severely impair RNA binding [76]. All these stud- 
ies, together with the phenotype of the individual with the 
point mutation, suggest hat FMRP has an RNA binding 
function within the cell. These studies await the demon- 
stration that FMRP is associated with RNA/protein com- 
plexes in vivo and it will be of particular interest to 
identify the cellular RNAs involved. 
7. Expression studies 
Studies on the expression of FMR1 show a high level of 
FMR1 expression in brain and testis [27,77]. Most other 
tissues show expression at a variable, but generally very 
low level. Interestingly, in the heart only small (~  1.4 kb) 
mRNA species are seen, rather than the usual 4.4 kb 
transcript [78]. This is suggestive of tissue-specific differ- 
ential splicing and, since mitral valve defects have been 
observed in fragile X syndrome, there may be physio- 
logical implications in the finding, Alternatively spliced 
forms of FMR1 have been demonstrated in several tissues 
using PCR of reverse transcribed cellular mRNAs [64]. 
However, similar studies have yet to be reported in heart. 
Expression of FMR1 during development has been 
studied by the use of in situ hybridisation i the develop- 
ing mouse [78] and in human fetal brain [79]. In the mouse 
embryo, fmrl expression is detected throughout all tissues 
from the earliest stage studied (7 days gestation) until day 
10, after which expression becomes more abundant in 
specific organs and regions, particularly in areas of the 
brain, liver and heart. The tissue specific variation be- 
comes even more marked in the adult mouse, where high 
levels of expression are seen in the brain, testes, ovaries, 
thymus, oesophagus and spleen while there is no apparent 
expression i muscle, heart or aorta and only a low level of 
expression i  most other tissues. The expression of FMR1 
has been localised more precisely in the human fetal brain 
at two stages of development [79]. In 8- and 9-week-old 
fetuses, FMR1 mRNA is present in the proliferating and 
migrating cells of the nervous ystem, in the retina and in 
some non-nervous tissues. In 25-week-old fetuses, FMR1 
mRNA is restricted to differentiated structures with the 
highest level being present in cholmergic neurons of the 
nucleus basilis magnocellularis and in the pyramidal neu- 
rons of the hippocampus. 
The temporal and spatial pattern of expression of FMRI 
in the embryo may explain the heterogeneous phenotype 
often seen in fragile X patients. 7['his could arise from 
individual differences in when and where during fetal 
development the transition from premutation to full muta- 
tion, and subsequent methylation, occurs. 
Antibodies raised to fusion proteins and synthetic pep- 
tides derived from FMR1 cDNA have been used to lo- 
calise the protein at the subcellular level [80,81]. Immuno- 
histochemical detection of FMR1 in the human central and 
peripheral nervous system localised it to neuron rich re- 
gions and not to the supporting cells. In the cerebellum, 
Purkinje cells lying between the granular and molecular 
layers were most intensely stained. Prominent staining was 
also seen in the granular layer, which consists mainly of 
small neurons. Staining in the brain cortex was confined 
also to neurons, particularly the cell bodies, with axons 
and dendrites being very poorly stained. In the testis, the 
protein was found exclusively in spe~-rnatogonia, with more 
mature cells being negative. No significant antibody la- 
belling was observed in tissues of mesodermal origin, 
including the heart while all tissues of epithelial origin 
showed labelling, although at a lower level than that seen 
in the brain and testis. Interestingly, significant expression 
of the protein was particularly abundant in actively divid- 
ing cells. This situation contrasts with that seen in the 
brain, where only terminally differentiated neurons are 
labelled, but is in agreement with the mRNA in situ 
hybridisation data, which also suggest a high level of 
expression during cell division with a later specificity in 
regions of the brain. It is possible that FMR1 has more 
than one promoter esponding to different regulatory sig- 
nals, as is the case for other genes with dual or complex 
tissue specific expression patterns. 
FMR1 protein transiently expressed in Cos-7 cells 
[80,81] is found almost exclusively in the cytoplasm. This 
is rather surprising, in view of its predicted role as an RNA 
binding protein, since proteins belonging to the hnRNP 
family have been observed almost exclusively in the nu- 
cleus [82-86]. However ecent work has shown there can 
be shuttling of some members of the hnRNP family pro- 
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teins between the nucleus and cytoplasm [87]. This sug- 
gests that these proteins may also have functions within 
the cytoplasm. They may be involved in mRNA 
metabolism, such as the regulation of mRNA translation, 
stability and localisation. Most hnRNP proteins have sig- 
nals which enable them to enter the nucleus [88], and the 
FMR1 protein contains a nuclear localisation signal near to 
its C-terminus which would suggest hat it also has the 
ability to move between these cellular compartments. 
8. Trinucleotide repeats and human disease 
The finding of the trinucleotide xpansion in fragile X 
syndrome signalled the identification of a new class of 
human mutations for which the term 'dynamic mutations' 
has been coined (for review see Sutherland and Richards 
[89]). The term is used to describe the unstable and 
continuously changing nature of the mutation. Myotonic 
dystrophy (DM) [90-95], Kennedy's disease (SBMA) [96], 
Huntington's disease (HD) [97], spinocerebellar ataxia 
(SCA1) [98] and dentatorubral-pallidoluysian atrophy 
(DRPLA) [99,100] have all been found to involve expan- 
sions of a CAG triplet repeat located in different positions 
within their genes. Another fragile site on the X chromo- 
some (FRAXE) associated with mild mental retardation 
has a similar repeat structure to FMR1, with an expanded 
CGG repeat lying close to a CpG island which is hyperme- 
thylated in affected individuals [61]. 
The seven disorders characterised by trinucleotide re- 
peats have many features in common and these are de- 
scribed in Table 1. All except one affect neuronal cells as 
their primary target. Fragile X syndrome results in mental 
retardation and is expressed specifically in neurons. In 
FRAXE, where the gene has not yet been identified, af- 
fected individuals exhibit mild mental retardation which 
manifests primarily as learning difficulties. The pheno- 
types of HD, SCAI, SBMA and DRPLA show the most 
striking similarities. Each is due to loss of particular 
subsets of neurons over time. In HD, cells of the striatum 
degenerate, resulting in chorea and eventual loss of cogni- 
tive functions. SCA1 shows loss of the neurons in the 
inferior olive in the cerebellum and brain stem, resulting in 
ataxia and motor weakness. In SBMA, dorsal root ganglia 
cells and motor neurons of the spinal and bulbar roots 
show degeneration, leading to muscular atrophy. DRPLA 
shows combined degeneration of the dentatorubral (cere- 
bellar efferent) and pallidoluysian systems leading to pro- 
gressive myoclonus, epilepsy, ataxia and dementia. DM 
differs somewhat from the other six disorders in that while 
there is neuronal involvement, muscle appears to be the 
primary tissue affected. 
In common with fragile X syndrome, all of the disor- 
ders involving trinucleotide repeats how genetic anticipa- 
tion. This manifests as variability in penetrance, a trend 
towards a more severe phenotype over generations or an 
earlier age of onset. Three of the mutations are X-linked 
(Fragile X syndrome, FRAXE and SBMA), while the 
others are autosomal (DM chromosome 19; HD chromo- 
some 4; SCA1 chromosome 6; DRPLA chromosome 12). 
Apart from the presence of the trinucleotide repeat the 
genes show no similarities in their sequences. 
In all the disorders where the gene has been identified, 
the trinucleotide repeat sequence is localised within the 
transcribed portion of the gene. This may suggest a func- 
tional basis for the trinucleotide repeats. In four of the 
disorders (HD, SCA1, SBMA and DRPLA) the repeats lie 
within the protein coding region and give rise to polyglu- 
tamine tracts. It may be significant hat the repeats in both 
fragile X syndrome and DM lie in the untranslated region 
(UTR) of the gene (5' and 3' respectively). The expansions 
in the latter two disorders are very large, with increases of 
up to a hundred-fold, and as such would be unlikely to be 
tolerated within coding regions. This contrasts with HD, 
SCA1, SBMA and DRPLA where the repeat expansions 
are relatively small, and never exceed 100 repeats. The 
resulting protein products of these genes act in a manner 
consistent with a gain in function. This is most obvious in 
SBMA where the gene encodes an androgen receptor. 
Deletions within the gene cause loss of function resulting 
in testicular feminisation but not the muscular atrophy 
phenotype [94]. The mutation in the fragile X syndrome 
gives rise to a loss of function, due to abnormal hyperme- 
thylation. The situation in DM is far from clear. The 
product of the gene is a protein kinase (DM kinase). 
However the effect of the expansion in the 3' UTR has not 
Table 1 
Disorders associated with trinucleotide repeat expansions 
Disease Repeat seq. Range 
normal disease 
Methylation Location of repeat Functional change 
Fragile X syndrome CGG 6-50 
FRAXE GCC 6-25 
Myotonic dystrophy CTG 5-37 
SBMA CAG 12-34 
Huntington's disease CAG 11-36 
SCA 1 CAG 19-36 
DRPLA CAG 8-25 
200-2000 + 
200-850 + 
50-2000 
40-62 
42-100 
43-81 
54-68 
yes  
yes 
no 
no  
no  
no  
no  
1 st exon 5' UTR 
90 
last exon 3' UTR 
I st exon coding 
1st exon coding 
? exon coding 
? exon coding 
loss of function 
99 
? gain of function, ? mRNA stability 
gain of function 
? gain of function 
? gain of function 
? gain of function 
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been ascertained. The inheritance of the disorder is domi- 
nant, suggesting a gain-of-function mutation and it has 
been postulated that the increase in length of the 3' UTR 
causes enhanced mRNA stability leading to overexpression 
or inappropriate expression of the gene [ 101,102]. 
9. Prospects 
show any abnormal brain pathologic or overt behavioural 
or learning malfunctions. Much work is being focussed on 
the biochemistry of the FMR1 gene product and its possi- 
ble role in RNA binding. This will be essential in elucidat- 
ing the role of the gene product in intracellular events, and 
may give added impetus to the expanding field of RNA 
processing. The prospect of effective treatment for this 
disease may then become an attainable goal. 
The involvement of trinucleotide repeats in neurological 
syndromes with unusual inheritance patterns has led to a 
search for candidate genes containing triplet repeats which 
may be responsible for other disorders [103-105]. In fact 
the DRPLA gene was isolated by searching the databank 
for cloned genes containing CAG repeats and using these 
to analyse patient DNA. The identification of such genes 
will have wide implications, both in terms of increasing 
knowledge about the functioning of neural cells within the 
brain and because it casts doubt on the long-held belief 
that DNA is a stable entity. 
Trinucleotide repeat expansions have also provided ex- 
planations for a variety of phenomena which had been 
poorly understood. Genetic anticipation, incomplete pene- 
trance and variable expression are all found where such 
expansions are the molecular basis for the disease. It is 
also becoming apparent that this type of mutation may be 
limited to humans, since the trinucleotide repeats so far 
examined in other species have not shown the same degree 
of polymorphism or tendency to expansion. 
The identification three years ago of the gene defect 
involved in fragile X syndrome has had enormous impact 
on the diagnosis of the disease. The expensive and time 
consuming cytogenetic analysis of chromosome fragility 
has been largely replaced by detection of the CGG repeat 
by PCR or Southern analysis of DNA. Prenatal diagnosis 
can now be performed in early pregnancy and is offered to 
families of fragile X individuals. There have been propos- 
als, notably in the United States, to extend this test to more 
widespread population screening on the basis of the high 
frequency of fragile X syndrome. However, there is debate 
regarding the ethical implications of such a programme. 
The disease is not life-threatening, but rather gives rise to 
individuals with mental and behavioural characteristics 
which do not lie within the accepted normal range. Fur- 
thermore, due to the incomplete penetrance displayed by 
the disorder the phenotypic onsequences can range from 
very severe mental retardation to only slight behavioural 
problems. In addition, there is no prospect in the near 
future for effective treatment of the disorder either by 
conventional methods or by gene therapy, although some 
symptomatic treatment is being undertaken [106]. 
Despite intensive efforts, the precise molecular events 
which give rise to the fragile X phenotype are still un- 
known. Transgenic mice which lack the mouse homologue 
of FMR1 have been generated [107,108] but, although 
these animals have enlarged testes, they do not appear to 
10. Note added in proof: 
Since this review was written, expansion of a CAG 
triplet repeat in a gene on chromoso~aae 14q32.1 giving rise 
to Machado-Joseph disease [109] and three further CGG 
triplet expansions associated with chromosomal fragility 
[110-112] have been described. Thi~ brings the number of 
examples of trinucleotide repeat amplifications to eleven. 
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